Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Sutton

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
NPJ Breast Cancer|September 19, 2023
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical modelsLorna Hopcroft, Eleanor M Wigmore, Stuart C Williamson, et al.
Nature Metabolism|March 20, 2019
AMPK activation protects against diet induced obesity through Ucp1-independent thermogenesis in subcutaneous white adipose tissueAlice E Pollard, Luís Martins, Phillip J Muckett, et al.
NPJ Breast Cancer|August 5, 2023
Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical modelsLorna Hopcroft, Eleanor M Wigmore, Stuart C Williamson, et al.
Frontiers in Immunology|July 3, 2025
A comprehensive welfare scoring system for graft versus host disease clinical assessment in humanised mouse models used for pharmaceutical researchAlice Nowak, Rebecca Marlow, Kelli Ryan, et al.
Analytical Chemistry|January 10, 2022
Method To Visualize the Intratumor Distribution and Impact of Gemcitabine in Pancreatic Ductal Adenocarcinoma by Multimodal ImagingNicole Strittmatter, Frances M Richards, Alan M Race, et al.
Cell|April 3, 2025
Therapeutic potential of allosteric HECT E3 ligase inhibitionAlexander M K Rothman, Amir Florentin, Florence Zink, et al.
Cancer Research|September 19, 2023
The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor ResistanceMandy Lawson, Natalie Cureton, Susana Ros, et al.
Nature Communications|February 24, 2024
The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironmentElizabeth L Hardaker, Emilio Sanseviero, Ankur Karmokar, et al.
Science (New York, N.Y.)|March 3, 2022
Fly Cell Atlas: A single-nucleus transcriptomic atlas of the adult fruit flyHongjie Li, Jasper Janssens, Maxime De Waegeneer, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
NPJ Breast Cancer|September 19, 2023
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical modelsLorna Hopcroft, Eleanor M Wigmore, Stuart C Williamson, et al.
Nature Metabolism|March 20, 2019
AMPK activation protects against diet induced obesity through Ucp1-independent thermogenesis in subcutaneous white adipose tissueAlice E Pollard, Luís Martins, Phillip J Muckett, et al.
NPJ Breast Cancer|August 5, 2023
Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical modelsLorna Hopcroft, Eleanor M Wigmore, Stuart C Williamson, et al.
Frontiers in Immunology|July 3, 2025
A comprehensive welfare scoring system for graft versus host disease clinical assessment in humanised mouse models used for pharmaceutical researchAlice Nowak, Rebecca Marlow, Kelli Ryan, et al.
Analytical Chemistry|January 10, 2022
Method To Visualize the Intratumor Distribution and Impact of Gemcitabine in Pancreatic Ductal Adenocarcinoma by Multimodal ImagingNicole Strittmatter, Frances M Richards, Alan M Race, et al.
Cell|April 3, 2025
Therapeutic potential of allosteric HECT E3 ligase inhibitionAlexander M K Rothman, Amir Florentin, Florence Zink, et al.
Cancer Research|September 19, 2023
The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor ResistanceMandy Lawson, Natalie Cureton, Susana Ros, et al.
Nature Communications|February 24, 2024
The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironmentElizabeth L Hardaker, Emilio Sanseviero, Ankur Karmokar, et al.
Science (New York, N.Y.)|March 3, 2022
Fly Cell Atlas: A single-nucleus transcriptomic atlas of the adult fruit flyHongjie Li, Jasper Janssens, Maxime De Waegeneer, et al.
Pageof 3